The results of business activities of Grindeks Concern for 9 months of 2007 are
positive - production and sales values have been increasing in pursuance of
development plans accepted by the company.
Grindeks's turnover has reached 38,06 million lats after 9 months of 2007, this
means that the turnover has increased by 23,9% in comparison with the analogous
period of 2006.
Gross income of the company is 20,01 million lats for 9 months of 2007, and it
is by 18,6% more than for the analogous period of 2006. Net income of the
company for the period under review has reached 4,9 million lats.
“These results are more than satisfying - volumes of production and sales
increase according to promoted development plan of the company. In 9-month
period of 2007, Grindeks has significantly increased investments in product
research and development, as well as expansion of the representative offices
and boosting awareness of the company in the strategically important markets,“
Janis Romanovskis, Chairman of the Board of the JSC Grindeks, commenting on
companies financial data.
Grindeks is the leading pharmaceutical company in the Baltic States
specializing in the manufacturing and sales of heart and cardiovascular,
central nervous system and anti-cancer medications. Its concern consists of
four subsidiary companies in Latvia, Estonia and Russia as well as ten
representative offices. Products of the company are exported to more than 40
countries. Main markets are the Baltic States, Russia and other CIS countries,
Japan, USA. Grindeks shares are listed in the Official List of Riga Stock
Exchange.
